EraCal Therapeutics has closed an oversubscribed seed financing round, announced a statement. Among the investors were Bernina BioInvest, Redalpine, the UZH Life Sciences Fund and private investors.
The Zurich company is developing the appetite suppressant Era-107 to help people lose weight and avoid other diseases. Boasting a more precise mode of action than existing drugs, Era-107 is described as being more effective and causing fewer side effects. With the new funds, EraCal Therapeutics plans to drive the pre-clinical development.
EraCal Therapeutics was founded as a spin-off from the University of Zurich and Harvard University in Zollikon. It previously secured funding from the Venture Kick Competition and in June 2019, received 1 million Swiss francs from the Novartis Venture Fund and the UZH Foundation.
More news
Meet with an expansion expert
Is Greater Zurich on your expansion radar? We support you on every step of your expansion journey - from location evaluation to fact finding visits.
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Location evaluation support to find the ideal base for your business
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space
- And much more, customized to meet your needs.